Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)), Alexa Fluor™ 750, Novus Biologicals™
SDP

Human Monoclonal Antibody

Supplier:  Novus Biologicals NBP275913AF750

Catalog No. NP27913A70


Only null left
Add to Cart

Description

Description

OX40 Ligand/TNFSF4 Monoclonal specifically detects OX40 Ligand/TNFSF4 in Human samples. It is validated for Flow Cytometry.
Specifications

Specifications

OX40 Ligand/TNFSF4
Monoclonal
Alexa Fluor 750
50 mM sodium borate with 0.05% sodium azide
TNFSF4
Oxelumab binds to human OX40L, the ligand of OX40, stimulatory receptor that is expressed on activated T cells, natural killer (NK) cells and natural killer T (NKT) cells.
0.1 mL
Primary
Binds to human OX40L.
Store at 4°C in the dark.
Flow Cytometry
R4930 (Oxelumab)
Flow Cytometry
CD134 ligand, CD134L, CD252, CD252 antigen, Glycoprotein Gp34, gp34, OX40 antigen ligand, OX40 ligand, OX40L, OX-40L, OX4OL, TAX transcriptionally-activated glycoprotein 1, tax-transcriptionally activated glycoprotein 1 (34kD), tax-transcriptionally activated glycoprotein 1, 34kD, tumor necrosis factor (ligand) superfamily, member 4, tumor necrosis factor ligand superfamily member 4, TXGP1
Human
Protein A purified
Cancer, Cell Cycle and Replication, Immunology
7292.0
Human
IgG1 κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.